Ainos(US:AIMD)2025-08-13 20:15Revenue Performance - Ainos, Inc. reported revenues of $4,663 in Q2 2025, compared to nil in Q2 2024, primarily from VELDONA pet supplements sales in Taiwan [128]. - In H1 2025, the company reported revenues of $110,870, a significant increase of $90,141 (435%) compared to $20,729 in H1 2024 [138]. Cost of Revenues - The cost of revenues decreased to $937 in Q2 2025 from $25,373 in Q2 2024, attributed to lower sales volume as the company shifts focus to the AI Nose platform [128]. - The cost of revenues decreased to $19,170 in H1 2025 from $52,127 in H1 2024, reflecting a reduction of $32,957 (63%) due to changes in product compositions [140]. Gross Profit - Gross profit in Q2 2025 was $3,726, a significant improvement from a gross loss of $25,373 in Q2 2024, due to increased sales volume [129]. - Gross profit in H1 2025 was $91,700, compared to a gross loss of $31,398 in H1 2024, marking an improvement of $123,098 (392%) due to product composition changes [141]. Research and Development Expenses - Research and development (R&D) expenses were $1,911,800 in Q2 2025, a decrease of 3% from $1,978,756 in Q2 2024, reflecting reduced co-research and staffing expenditures [131]. - R&D expenses decreased by $427,520 (11%) to $3,635,884 in H1 2025 from $4,063,404 in H1 2024, attributed to reduced clinical trial fees and staffing expenditures [143]. Selling, General and Administrative Expenses - Selling, general and administrative (SG&A) expenses rose to $1,837,613 in Q2 2025, a 76% increase from $1,044,880 in Q2 2024, driven by higher share-based compensation [133]. - SG&A expenses increased by $1,290,076 (62%) to $3,364,374 in H1 2025 from $2,074,298 in H1 2024, primarily due to higher share-based compensation [145]. Operating Loss - The company's operating loss increased by 23% to $3,745,687 in Q2 2025 from $3,049,009 in Q2 2024, as resources were invested in growth strategies [135]. - The company's operating loss increased by $739,458 (12%) to $6,908,558 in H1 2025 compared to $6,169,100 in H1 2024, reflecting ongoing investments in growth strategies [147]. Net Loss - Net loss for H1 2025 was $7,371,012, an increase of $861,180 (13%) from $6,509,832 in H1 2024, driven by exchange rate fluctuations and expanding operating expenses [149]. Cash Position - As of June 30, 2025, Ainos had cash and cash equivalents of $1,223,184, with plans to seek additional financing to support operations [122]. - As of June 30, 2025, the company had available cash of $1,223,184, down from $3,892,919 as of December 31, 2024 [150]. - Cash used in operating activities decreased by $893,892 in H1 2025 compared to H1 2024, primarily due to increased non-cash expenses and changes in working capital [151]. - The company anticipates that cash reserves, business revenues, and potential debt financing will fund operations over the next twelve months, with no assurance of achieving profitability [154]. Strategic Initiatives - Ainos plans to enter commercial pilot phases for the AI Nose platform across various sectors in the second half of 2025 [111]. - The company is advancing clinical trials for its VELDONA platform in Taiwan, focusing on oral warts in HIV-positive patients and Sjögren's syndrome [118]. - Ainos has formed strategic partnerships to expand the use of AI Nose technology into robotics and industrial applications [109].